Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment

Outcomes of Cutaneous T-Cell Lymphoma and Chronic Graft-Versus-Host Disease in Patients Treated With Extracorporeal Photopheresis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01460914

Enrollment

Registered

2011-10-27

Start date

2011-10-01

Completion date

2015-01-06

Last updated

2024-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous T Cell Lymphoma, Graft Versus Host Disease

Keywords

ECP, CTCL, Extracorporeal photopheresis, Cutaneous T Cell Lymphoma, GVHD, Graft versus host disease

Brief summary

Extracorporeal Photopheresis (ECP) is a form of apheresis and photodynamic therapy in which the peripheral blood is treated with 8-methoxypsoralen, which is then activated with UV light. ECP is currently a standard therapy for cutaneous T-cell lymphoma (CTCL) and is also effective for graft-versus-host disease (GVHD). The investigators would like to study the outcomes (response rates) of patients receiving ECP treatment and other factors relating to their disease and treatment, as well as procedural events, such as complications.

Detailed description

The investigators intend to report outcomes from the inception of this procedure at Dartmouth-Hitchcock Medical Center (DHMC) in May 2008 through 9/30/11. Additionally, the investigators would like to maintain a prospective database of these patients so that new patient data can be collected for updating of outcomes.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who receive Extracorporeal Photopheresis treatment * Treated at Dartmouth-Hitchcock Medical Center * Must be 18 years or older

Exclusion criteria

\- None specified

Design outcomes

Primary

Measure	Time frame	Description
Response rates	1 year	Response rates to ECP treatment

Secondary

Measure	Time frame	Description
Complications	1 year	Complications to ECP procedures

Countries

United States

Outcome results